Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.56 |
| ▸ | RXRB | P28702 | 3/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 4/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908909 | 1.00 | RXRA (0.56) | RXRARXRBSRD5A2HCRTR1HCRTR2 | |
| SCHEMBL16749640 | 0.82 | RARB (0.68) | RARBPLA2G4B | |
| SCHEMBL16749635 | 0.81 | MAPT (0.54) | RXRARXRBSRD5A2RARBRARG | |
| SCHEMBL21182646 | 0.80 | RXRA (0.64) | RXRARXRBRARBRARGEGFR | |
| SCHEMBL25125396 | 0.79 | TSHR (0.57) | RXRARXRBSRD5A2HCRTR1HCRTR2 | |
| SCHEMBL7972144 | 0.78 | RXRA (0.63) | RXRARXRBHCRTR1HCRTR2RARB | |
| SCHEMBL202683 | 0.76 | PLA2G4B (0.74) | RXRARXRBSRD5A2HCRTR1HCRTR2 | |
| SCHEMBL1721733 | 0.76 | TSHR (0.62) | RXRARXRBSRD5A2HCRTR1HCRTR2 | |
| SCHEMBL1568239 | 0.76 | RXRA (0.54) | RXRARXRBHCRTR1HCRTR2EGFR | |
| SCHEMBL16749637 | 0.74 | RXRA (0.66) | RXRARXRBRARBRARGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629639-B2 | Spacer for a spiral wound membrane | EVOVE LTD (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4397399-A2 | MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES | G2O Water Technologies Limited (GB) | 2024-07-10 | — | — | EP | disclosed |
| US-20240157304-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | EVOVE LTD (GB) | 2024-05-16 | — | — | US | disclosed |
| US-20240149223-A1 | MEMBRANE DEVICE | EVOVE LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4304765-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | Evove Ltd (GB) | 2024-01-17 | — | — | EP | disclosed |
| EP-4304766-A1 | MEMBRANE DEVICE | Evove Ltd (GB) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022189785-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | EVOVE LTD (GB) | 2022-09-15 | — | — | WO | disclosed |
| EP-3774001-A1 | MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES | G2O Water Technologies Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629639-B2 | Spacer for a spiral wound membrane | AQP1, AQP3, AQP4 | RXRA 3105/4885RXRB 3668/4885SRD5A2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.